Articles

Find an Article

Filter articles

Applied Filters

Showing 81 to 90 of 322 results

Speeding up the fight against Zika

Brazil02-06-2018Ana Paula Jardim and Andréa Granthon

Brazil’s IP office now expedites patent applications directed to the Zika virus and other neglected diseases, as Ana Paula Jardim and Andréa Granthon of Luiz Leonardos report.

Medicine for the millions

Brazil01-06-2018Alice Rayol Sandes

Product development partnerships are likely to provide great opportunities for companies seeking to market biosimilar products in Brazil, where there is a huge reliance on public healthcare. Alice Rayol Sandes of Di Blasi, Parente & Associados has more.

Keeping trade fair

Mexico01-06-2018Hector Chagoya

As Mexico prepares for a presidential election in 2018, pharma IP owners are hoping that the progress made in trade negotiations is not undone. Hector Chagoya of Becerril Coca & Becerril reports.

Post-grant proceedings: shaping the biotech landscape

US01-06-2018Jennifer Fox

It is certain that both inter partes and post-grant reviews will continue to shape the landscape for biologics patents and biosimilars, says Jennifer Fox of Brinks Gilson & Lione.

Patent backlog in Brazil: slow, but welcome, progress

Brazil31-05-2018Kene Gallois and Ricardo Nunes

Brazil’s patent backlog has long caused concern for IP owners, particularly those in the pharmaceutical industry, but progress is being made, as Kene Gallois and Ricardo Nunes of Daniel Legal & IP Strategy report.

Can a computer invent a drug?

International, US31-05-2018MaryAnne Armstrong

Artificial intelligence is being used increasingly in the pharma and biotech industries, and questions are being asked about the legal status of innovations created by the technology, as MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch reports.

A growing business: soybeans in Brazil

Brazil29-05-2018Gabriel Di Blasi and Matheus Gil do Amaral

Research and development, strong IP rights and good international relations are all factors in Brazil’s rise as a soybean-producing powerhouse, as Gabriel Di Blasi and Matheus Gil do Amaral of Di Blasi Parente & Associados report.

Clearing a way through the CRISPR patent jungle

Belgium, Denmark, International08-05-2018Timo Minssen, Esther van Zimmeren, Jakob Wested

There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested.

Eli Lilly: the trials and tribulations of antibody patents

17-04-2018

Courts have not always been able to appreciate the complexities around antibody patents, causing problems for innovation and investment, says Eli Lilly patent counsel Duane Marks in an interview with LSIPR.

AstraZeneca: no time for time-wasting

US08-03-2018

The IP team at AstraZeneca must “ruthlessly” prioritise how it spends time and resources, its vice president of global IP explained in an interview.

Showing 81 to 90 of 322 results

LSIPR